Population-level health and economic impacts of introducing Vaccae vaccination in China: a modelling study
Open Access
- 31 May 2023
- journal article
- research article
- Published by BMJ in BMJ Global Health
- Vol. 8 (5) , e012306
Abstract
Introduction Given the ageing epidemic of tuberculosis (TB), China is facing an unprecedented opportunity provided by the first clinically approved next-generation TB vaccine Vaccae, which demonstrated 54.7% efficacy for preventing reactivation from latent infection in a phase III trial. We aim to assess the population-level health and economic impacts of introducing Vaccae vaccination to inform policy-makers. Methods We evaluated a potential national Vaccae vaccination programme in China initiated in 2024, assuming 20 years of protection, 90% coverage and US$30/dose government contract price. An age-structured compartmental model was adapted to simulate three strategies: (1) no Vaccae; (2) mass vaccination among people aged 15–74 years and (3) targeted vaccination among older adults (60 years). Cost analyses were conducted from the healthcare sector perspective, discounted at 3%. Results Considering postinfection efficacy, targeted vaccination modestly reduced TB burden (~20%), preventing cumulative 8.01 (95% CI 5.82 to 11.8) million TB cases and 0.20 (0.17 to 0.26) million deaths over 2024–2050, at incremental cost-effectiveness ratio of US$4387 (2218 to 10 085) per disability adjusted life year averted. The implementation would require a total budget of US$22.5 (17.6 to 43.4) billion. In contrast, mass vaccination had a larger bigger impact on the TB epidemic, but the overall costs remained high. Although both preinfection and postinfection vaccine efficacy type might have a maximum impact (>40% incidence rate reduction in 2050), it is important that the vaccine price does not exceed US$5/dose. Conclusion Vaccae represents a robust and cost-effective choice for TB epidemic control in China. This study may facilitate the practice of evidence-based strategy plans for TB vaccination and reimbursement decision making.Keywords
Funding Information
- Science and Technology Support Program of Jiangsu Province (BE2015655)
- Ministry of Science and Technology of the People's Republic of China (2022YFC2304901)
- Jiangsu Provincial Department of Education (SJCX22_1638)
- National Natural Science Foundation of China (81370520)
This publication has 33 references indexed in Scilit:
- Age-targeted tuberculosis vaccination in China and implications for vaccine development: a modelling studyThe Lancet Global Health, 2019
- Household-Contact Investigation for Detection of Tuberculosis in VietnamNew England Journal of Medicine, 2018
- Multi-stage subunit vaccines against Mycobacterium tuberculosis: an alternative to the BCG vaccine or a BCG-prime boost?Expert Review of Vaccines, 2017
- Tuberculosis control strategies to reach the 2035 global targets in China: the role of changing demographics and reactivation diseaseBMC Medicine, 2015
- Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countriesProceedings of the National Academy of Sciences, 2014
- Population Health Impact and Cost-Effectiveness of Tuberculosis Diagnosis with Xpert MTB/RIF: A Dynamic Simulation and Economic EvaluationPLOS Medicine, 2012
- Predictive factors for latent tuberculosis infection among adolescents in a high-burden area in South Africa.2011
- HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health responseThe Lancet, 2009
- Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnosticsProceedings of the National Academy of Sciences, 2009
- Latent Tuberculosis InfectionNew England Journal of Medicine, 2002